Brief: Orchard Therapeutics PLC Expects To File A BLA For Otl-103 In U.S. In 2022
11/01/2021 13:42
Jan 11 (Reuters) - Orchard Therapeutics PLC ORTX.O :
* ORCHARD THERAPEUTICS PLC - PREPARATIONS ON TRACK FOR FIRST
HALF
2021 COMMERCIAL LAUNCH OF LIBMELDY
* ORCHARD THERAPEUTICS PLC - EXPECTS TO FILE A BLA FOR
OTL-103 IN
U.S. IN 2022
* ORCHARD THERAPEUTICS PLC - ENDED 2020 WITH ABOUT $192
MILLION OF
CASH AND INVESTMENTS
Source text for Eikon: ID:nGNX2SnMFn
Further company coverage: ORTX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Orchard Therapeutics
See all newsBrief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln